Skip to content

Comparison of two drugs for pain relief in hernia surgeries

Comparison of efficacy of Nalbuphine-Levobupivacaine combination with Levobupivacaine alone in ultrasound guided Transversus Abdominis Plane block in open inguinal hernia repair surgeries : A randomised control trial - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/11/076103
Enrollment
60
Registered
2024-11-01
Start date
Unknown
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Levobupivacaine: 20ml Levobupivacaine 0.25% +1 ml Normal Saline given in TAP block. Control Intervention1: Levobupivacaine with Nalbuphine: 20ml Levobupivacaine 0.25% + 10mg (1ml) Nalbu

Sponsors

Himanshi Singh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Informed consent, all patients undergoing unilateral open inguinal hernioplasty, ASA class 1 and 2

Exclusion criteria

Exclusion criteria: ASA grade III and IV, Allergy to the study drug, Communication difficulties being unable to comprehend visual analogue scale, Bleeding diathesis, Patients with deranged liver and kidney functions, BMI less than 18 and more than 35, Surgery duration of more than 2 hours

Design outcomes

Primary

MeasureTime frame
To assess the time of first rescue analgesic (duration of analgesia) Timepoint: 0 mintues, 30 min, 60 min, 90 min, 120 min, 4 hours, 8 hours, 12 hours, 16 hours, 20 hours, 24 hours

Secondary

MeasureTime frame
To observe the visual analogue score (resting and ambulatory) for 24 hours, total number of analgesics required in 24 hours, to assess the haemodynamic parameters postoperatively, to observe the side effectsTimepoint: 24 hours

Countries

India

Contacts

Public ContactDr Sakshi

Ananta institute of medical sciences and research centre, Nathdwara, Rajsamand

drsakshiarora88@gmail.com9571241824

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026